Haemonetics Corporation (NYSE:HAE) had its price target boosted by Morgan Stanley from $43.00 to $51.00 in a research report report published on Thursday. They currently have an equal weight rating on the medical instruments supplier’s stock.

HAE has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Haemonetics Corporation from a buy rating to a hold rating in a research report on Tuesday, August 29th. BidaskClub upgraded shares of Haemonetics Corporation from a strong sell rating to a sell rating in a research report on Tuesday, August 8th. JMP Securities upgraded shares of Haemonetics Corporation from a market perform rating to an outperform rating and set a $50.00 price objective for the company in a research report on Thursday, July 13th. Barrington Research upgraded shares of Haemonetics Corporation from a market perform rating to an outperform rating and set a $48.00 price objective for the company in a research report on Tuesday, August 8th. Finally, Craig Hallum reiterated a hold rating and issued a $50.00 price objective (up previously from $40.00) on shares of Haemonetics Corporation in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $51.33.

Haemonetics Corporation (NYSE HAE) traded down $0.40 during midday trading on Thursday, reaching $54.52. 695,600 shares of the company were exchanged, compared to its average volume of 344,366. The firm has a market capitalization of $2,879.65, a P/E ratio of 33.45, a PEG ratio of 4.08 and a beta of 0.91. Haemonetics Corporation has a 52 week low of $36.44 and a 52 week high of $55.10. The company has a quick ratio of 1.51, a current ratio of 2.17 and a debt-to-equity ratio of 0.22.

Haemonetics Corporation (NYSE:HAE) last issued its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.07. The business had revenue of $225.40 million during the quarter, compared to the consensus estimate of $219.12 million. Haemonetics Corporation had a net margin of 0.50% and a return on equity of 11.16%. The company’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.38 earnings per share. equities analysts predict that Haemonetics Corporation will post 1.7 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/morgan-stanley-boosts-haemonetics-corporation-hae-price-target-to-51-00/1700905.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in HAE. Shine Investment Advisory Services Inc. acquired a new position in shares of Haemonetics Corporation during the 2nd quarter worth about $132,000. Riverhead Capital Management LLC raised its position in shares of Haemonetics Corporation by 79.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 1,507 shares during the last quarter. Pacad Investment Ltd. acquired a new position in shares of Haemonetics Corporation during the 2nd quarter worth about $174,000. Shelton Capital Management acquired a new position in shares of Haemonetics Corporation during the 2nd quarter worth about $204,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Haemonetics Corporation during the 2nd quarter worth about $260,000.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Analyst Recommendations for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.